Thanks for your post.
In such patients with low viral loads, I'll still recommend considering HAART- how strongly to encourage is dependent on the individual, for some following the CD4s over time can help provide an additional data point.
For others, it's important to bear in mind that there are patients who develop HIV-related complcations and malignancies at higher counts; moreover, waiting until counts are lower is now clearly associated with increased risks of drug-related side effects, including lipdystrophy.
In the end, it's still up to the patient to start. I try to provide a supportive environment for the patient no matter what the decision.
Hope this helps. BY
